Navigation Links
Pharmasset Reports Fiscal Year End 2008 Financial Results
Date:12/11/2008

rst calendar half of 2009.

PSI-7851

During 2008, Pharmasset nominated PSI-7851 as its lead, second generation nucleotide candidate for HCV. Preclinical data indicate that PSI-7851 could be up to 20 times more potent than R7128, raising the prospect that the drug might be used in fixed dose combinations in the future. The company plans to file an IND for PSI-7851 in the first calendar quarter of 2009.

"During 2008, Pharmasset made significant progress both in the clinic and on the corporate front," said Schaefer Price, Pharmasset's President and CEO. "We remain focused on maintaining this momentum and building a pipeline of differentiated antiviral candidates. Through our collaboration with Roche, the leader in HCV market, we plan to rapidly progress R7128 through phase 2 studies. The partnership is also exploring the paradigm changing model of an all oral (interferon sparing) regimen for HCV, which we believe would be the future of treatment. These efforts provide the groundwork for our next generation of nucleoside and nucleotide inhibitors, such as PSI-7851, that hold the potential for us to explore fixed dosed combinations."

Financial Results

For the fiscal year ended September 30, 2008 Pharmasset reported revenues of $1.9 million, compared with revenues of $22.0 million for the fiscal year 2007. The receipt of milestones totaling $20 million from Roche led to higher reported revenues in the fiscal year 2007.

Total costs and expenses for the fiscal year ended September 30, 2008 were $56.3 million as compared to $29.5 million for the same period in 2007. The increased operating expenses for fiscal year 2008 were primarily the result of an increase in Phase 3 registration clinical trial expenses for clevudine for the treatment of chronic HBV infection, as well as increased drug discovery activities and the administrative expenses of a public company.


'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
3. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
4. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
5. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Pharmasset Receives Notice of Allowance
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces ... available in its catalogue: Wireless ... RFID, Zigbee, UWB WWAN, WMAN, WLAN and ... Kalorama Information,s Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ...
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that a ... catalogue: Global Coatings for Medical Devices ... This report analyzes the worldwide markets ... by the following Product Segments: Active Coatings, Protective ... provides separate comprehensive analytics for the US, ...
(Date:8/20/2014)... LYNDHURST, N.J. , Aug. 20, 2014  Amerigen ... Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA ... Mecobalamin 0.5 mg Tablets into the ... of a marketing and distribution agreement with Sinochem ... product at its US FDA approved and China ...
Breaking Medicine Technology:Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
... primary endpoint not met; plausibly,confounded by survival ... YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImClone,Systems ... results from the EPIC study - a ... ERBITUX(R),(Cetuximab) plus irinotecan to irinotecan alone in ...
... ProNAi Therapeutics,Inc., a biopharmaceutical company pioneering a ... interference (DNAi), today,announced that its lead oncology ... vivo efficacy in,xenograft mice for a number ... difficult-to-treat Burkitt's Lymphoma., Dr. Richard D. Gill, ...
Cached Medicine Technology:Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma 2
(Date:8/20/2014)... PA (PRWEB) August 20, 2014 A ... products from the blood did not improve survival chances ... analysis led by experts at the University of ... published online today in the journal PLOS One ... standardly used for people with sudden kidney failure, may ...
(Date:8/20/2014)... Steven Reinberg HealthDay Reporter ... disorder that dismantles a baby,s immune system is twice as ... 3 million infants says. This is the first evaluation ... treatable condition known as severe combined immunodeficiency (SCID), or "Bubble ... of this condition by the boy in the bubble, who ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the most ... in recent years, developing or acquiring 2 million square ... more than $100 million last year alone. , In ... geographic regions and a wider array of product types ... an enhanced brand identity that includes a new logo, ...
(Date:8/20/2014)... 20, 2014 Understanding the impact ... physician stakeholders networks impacting the launch of new ... Canada, and Emerging Markets. , This Flash Report ... on stakeholder management needs for the melanoma market. ... targeted therapy investigational agents that are further improving ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Systems Operations, Security and, Maintenance ... ARLINGTON, Va., Oct. 16 Vangent, ... and business process outsourcing,solutions, today announced it ... Information and Decision Support (EIDS) Infrastructure,Operations, Security ...
... risk of asthma than their urban counterparts or even ... a University of Alberta study. , Analysis of ... 12 years in the ongoing Canadian National Longitudinal Survey ... in a farming environment had a lower risk of ...
... COLUMBUS, Ga., Oct. 16 Aflac Incorporated,(NYSE: AFL ... financial,results after the market closes on October 23, 2007. ... will,webcast a conference call scheduled for 9:30 a.m. (EDT) ... and CEO Dan,Amos will discuss third quarter results and ...
... STA Travel, the world,s largest student,and youth travel organization, and ... pandemic in Africa. Through the "Good Cents,Initiative", college students across ... to compose a song, direct a video or write an,essay ... where they,will work side by side with Keep A Child ...
... "I would have never,guessed that some of the best ... come from Planned Parenthood, the largest,abortion chain in the ... Days for Life., "People in more than 80 ... about half of the vigils are being conducted outside ...
... is commonly thought that men with low IQs sexually ... deviance, new research has found the men may sexually ... previously taken. , A team of North American ... an intellectual disability and a history of sexual offence ...
Cached Medicine News:Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:Farm kids have lower risk of asthma, study shows 2Health News:Aflac Incorporated to Release Third Quarter Results On October 23, 2007 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 3Health News:40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode 2Health News:'Corrective' sex education may make sexual offenders more dangerous 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: